UPDATES

$Immutep (IMMP.US)$ Biotechnology company Immutep (ASX:IMM) obtained positive survival data from the Insight-003 first phase trial, evaluating eftilagimod alpha in combination with Keytruda and chemotherapy for the first-line treatment of metastatic non-squamous non-small cell lung cancer, according to a Thursday filing with the Australian bourse.

The study results, with a minimum follow-up of 22 months, showed a median overall survival of 32.9 months, a median progression-free survival of 12.7 months, and a 24-month overall survival rate of 81%, the filing said.

Results also show no new safety signals.

Insight-003, led by the Frankfurt Institute of Clinical Cancer Research, is nearing patient enrollment completion, with further data from the trial expected in 2025, according to the filing.